A Phase 2 Study of Cyclo-Z in Subjects With Type 2 Diabetes
Public ClinicalTrials.gov record NCT03560271. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Study to Evaluate the Efficacy and Safety of Cyclo-Z in Subjects With Type 2 Diabetes
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a double-blind, randomized, placebo-controlled, parallel-group comparison study to evaluate the efficacy and safety of Cyclo-Z vs. placebo in adult subjects with type 2 diabetes. Approximately 20 clinical sites may be utilized in the United States so that approximately 300 subjects (a potential 20% screening failure rate) may be screened for total 28-week study period (2 weeks for screening, 24 weeks for treatment, and 2 weeks for safety follow-up).
Study identification
- NCT ID
- NCT03560271
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 256 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 17, 2018
- Primary completion
- Jun 24, 2019
- Completion
- Jul 14, 2019
- Last update posted
- Nov 17, 2019
2018 – 2019
United States locations
- U.S. sites
- 20
- U.S. states
- 9
- U.S. cities
- 19
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Study Site 29 | Anniston | Alabama | 36207 | — |
| Study Site 26 | Birmingham | Alabama | 35216 | — |
| Study Site 27 | Chula Vista | California | 91911 | — |
| Study Site 28 | La Mesa | California | 91942 | — |
| Study Site 10 | Montclair | California | 91763 | — |
| Study Site 23 | North Hollywood | California | 91606 | — |
| Study Site 13 | Coral Gables | Florida | 33134 | — |
| Study Site 19 | DeLand | Florida | 32720 | — |
| Study Site 14 | Miami | Florida | 33155 | — |
| Study Site 12 | Miami Beach | Florida | 33140 | — |
| Study Site 15 | Orlando | Florida | 32806 | — |
| Study Site 16 | St. Petersburg | Florida | 33711 | — |
| Study Site 21 | Peachtree Corners | Georgia | 30071 | — |
| Study Site 17 | Snellville | Georgia | 30078 | — |
| Study Site 20 | North Dartmouth | Massachusetts | 02747 | — |
| Study Site 30 | Caro | Michigan | 48723 | — |
| Study Site 24 | Las Vegas | Nevada | 89106 | — |
| Study Site 18 | Cleveland | Ohio | 44142 | — |
| Study Site 22 | San Antonio | Texas | 78220 | — |
| Study Site 11 | San Antonio | Texas | 78249 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03560271, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 17, 2019 · Synced Sep 3, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03560271 live on ClinicalTrials.gov.